Claims for Patent: 9,597,409

Summary for Patent: 9,597,409

Title:	Methods of treating cancer
Abstract:	The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
Inventor(s):	Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA)
Assignee:	ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA)
Application Number:	13/782,990
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,597,409
Patent Claims:	1. A method of treating NSCLC in an individual comprising administering to the individual a) an effective amount of a composition comprising nanoparticles comprising paclitaxel and an albumin and b) an effective amount of a platinum-based agent, wherein treatment is based upon the individual having squamous cellular carcinoma. 2. The method of claim 1, wherein the method comprises selecting the individual for treatment based on the individual having squamous cellular carcinoma. 3. The method of claim 1, wherein the effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is between about 50 mg/m.sup.2 and about 125 mg/m.sup.2. 4. The method of claim 1, wherein the composition comprising nanoparticles comprising paclitaxel and albumin is administered weekly. 5. The method of claim 1, wherein the effective amount of the platinum-based agent is between about AUC=2 and about AUC=6. 6. The method of claim 1, wherein the platinum-based agent is administered once every three weeks. 7. The method of claim 1, wherein the effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is 100 mg/m.sup.2 administered weekly and the effective amount of the platinum-based agent is AUC=6 administered once every three weeks. 8. The method of claim 1, wherein paclitaxel in the nanoparticles is coated with albumin. 9. The method of claim 1, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm. 10. The method of claim 1, wherein the NSCLC is Stage IIIB NSCLC or Stage IV NSCLC. 11. The method of claim 1, wherein the composition comprising nanoparticles comprising paclitaxel and albumin and the platinum-based agent are administered parenterally. 12. The method of claim 11, wherein the composition comprising nanoparticles comprising paclitaxel and albumin and the platinum-based agent are administered intravenously. 13. The method of claim 1, wherein the platinum-based agent is carboplatin. 14. The method of claim 1, wherein the individual is human. 15. The method of claim 1, wherein the method further comprises the administration of thoracic radiation. 16. The method of claim 15, wherein the effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is between about 20 mg/m.sup.2 to about 60 mg/m.sup.2 administered weekly, the effective amount of a platinum-based agent is between about AUC=2 to about AUC=6 administered weekly, and the thoracic radiation is between about 25 to about 40 fractions by either 3D conformal or intensity-modulated techniques concurrently. 17. The method of claim 1, wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 1:1 to about 9:1. 18. The method of claim 17, wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 9:1. 19. The method of claim 8, wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 1:1 to about 9:1. 20. The method of claim 9, wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 1:1 to about 9:1. 21. The method of claim 19, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm. 22. The method of claim 13, wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 1:1 to about 9:1. 23. The method of claim 22, wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 9:1. 24. The method of claim 22, wherein paclitaxel in the nanoparticles is coated with the albumin. 25. The method of claim 24, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm. 26. The method of claim 23, wherein paclitaxel in the nanoparticles is coated with the albumin. 27. The method of claim 26, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.